Shanghai InnoStar Bio-tech Co., Ltd. (InnoStar), was established in 2010. As a leading contract research organization, we adhere to the core values of “Science orientated, Quality first, Integrity & dedication, Win-win cooperation”, and strive for innovative and reputational services with high quality and excellence. Over the past decade, InnoStar has successfully passed GLP inspections by various national and international authorities, including US FDA, and received the GLP certification from the National Medical Products Administration (NMPA), OECD GLP certification GLP monitoring authority, AAALAC certification, and CAP certification from the College of American Pathologists (CAP), etc. Our business scope covers screening and discovery services, nonclinical pharmacodynamics, nonclinical pharmacokinetics, nonclinical safety evaluation, clinical sample bioanalysis, biomarkers and translational research. InnoStar was listed on the STAR Market of Shanghai Stock Exchange on September 3, 2024 (Stock code: 688710).

After years of development, InnoStar now owns nearly 60,000 square meters of modern laboratory and test facilities in Shanghai, Nantong, Shenzhen, Huangshan, and San Francisco, USA, building a staff team of over one thousand scientists and professional technicians, InnoStar has the industry-leading capability to provide one-stop new drug research and development services that are compliant with domestic and international application standards for global pharmaceutical companies and research institutions. As of December 31, 2024, we have cumulatively served more than 900clients worldwide. Domestically, we enabled 24 innovative drugs NDA/BLA approved, and more than 540 projects IND approved by NMPA CDE. Internationally, InnoStar has enabled more than 140 projects IND approved by various national authorities including the United States, the European Union, South Korea, Janpan and Australia, and enabled 3 innovative drugs NDA/BLA approved by FDA.

InnoStar is committed to providing one-stop service solutions to our clients in China and overseas. We are striving to be the scientific and technological innovation pioneer, the new drug R&D accelerator, and human life and health guardian.